P Christian Schulze

Gracie Square Hospital, New York, NY, New York City, New York, United States

Are you P Christian Schulze?

Claim your profile

Publications (149)878.07 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Myostatin (MSTN), a negative regulator of muscle growth and size, is increased after acute myocardial infarction(AMI) but timing of upregulation after injury is not known. In this study, we investigated the timing of the MSTN/AKT/p38 pathway activation in heart and skeletal muscle after AMI, as well as the potential effect of cardiac injury-related MSTN endocrine signaling on skeletal muscle and other circulating growth factors. Coronary artery ligation was performed in C57BL/6 mice at age 8 weeks to induce AMI. Mice were sacrificed at different time points (10m, 1h, 2h, 6h, 12h, 24h, 1 week, 2 weeks, 1 months and 2 months) after surgery (n=3 per time point, n=18 total). Cardiac and circulating MSTN upregulation occurred as early as 10 minutes after AMI. Two months after AMI, increased cardiac MSTN/SMAD2,3 and p38 together with decreased IGF-1/AKT signaling suggest an anti-hypertrophic profile. In skeletal muscle, an absence of local MSTN increase was accompanied by increased MSTN-dependent SMAD2,3 signaling, suggestive of paracrine effects due to cardiac-derived MSTN. Protein degradation by the ubiquitin-proteasome system in the skeletal muscle was also evident. Serum from 24h post-MI mice effectively induced a MSTN-dependent increase in atrogin1 and MuRF1. Our study shows that cardiac MTSN activation occurs rapidly after cardiac ischemia and may be involved in peripheral protein degradation in the skeletal muscle by activating atrogin1 and MuRF1. Copyright © 2014. Published by Elsevier Inc.
    Biochemical and Biophysical Research Communications 12/2014; · 2.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:Induction therapy with interleukin-2 receptor antagonists has been established as an effective immunosuppressive strategy in the management of heart transplant (HTx) recipients. We compared outcomes following HTx in patients receiving basiliximab, daclizumab, or no induction therapy.Methods and Results:We investigated post-transplant prognosis of patients receiving basiliximab (n=67), daclizumab (n=98) or no induction therapy (n=70). Patients treated with daclizumab (50.3±14.7 years) were younger than those receiving basiliximab (55.8±11.2 years) or no induction therapy (54.9±14.1 years; both P<0.05). Patients receiving either induction therapy showed better survival 1 year after HTx (95%) than those without induction therapy (82%; P<0.001). Survival was similar between patients receiving basiliximab and daclizumab. The incidence of acute cellular or antibody-mediated rejections did not differ among the groups. The main reason that patients did not receive induction therapy was ongoing infection (65.7%), which was more common in patients on ventricular assist device (VAD) support than those without VAD (76.1% vs. 45.8%; P=0.004). The VAD-related infection rate in the entire study cohort was 29.7% (35/118 VAD recipients).Conclusions:Survival following HTx was worse in patients not receiving induction therapy. No differences were noted in survival or the incidence of rejection between the daclizumab- and basiliximab-treated groups. Induction therapy was less used in patients with infection, which was related to prior VAD support.
    The Journal of Heart and Lung Transplantation 12/2014; · 5.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sepsis is a systemic inflammatory response that follows bacterial infection. Cardiac dysfunction is an important consequence of sepsis that affects mortality and has been attributed to either elevated inflammation or suppression of both fatty acid and glucose oxidation and eventual ATP depletion. Moreover, cardiac adrenergic signaling is compromised in septic patients and this aggravates further heart function. While anti-inflammatory therapies are important for the treatment of the disease, administration of anti-inflammatory drugs did not improve survival in septic patients. This review article summarizes findings on inflammatory and other mechanisms that are triggered in sepsis and affect cardiac function and mortality. Particularly, it focuses on the effects of the disease in metabolic pathways, as well as in adrenergic signaling and the potential interplay of the latter with inflammation. It is suggested that therapeutic approaches should include combination of anti-inflammatory treatments, stimulation of energy production, and restoration of adrenergic signaling in the heart.
    Current Heart Failure Reports 12/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives We evaluated neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C in comparison to established markers of renal function in patients with heart failure (HF). Background Patients with advanced HF develop progressive renal dysfunction. The renal biomarkers NGAL and cystatin C might improve prognostic assessment of patients with HF. Methods Serum samples were collected from 40 patients with stable HF (58±8 yrs, BMI 29.4±4.2 kg/m2), 40 HF patients undergoing ventricular assist device (VAD) implantation (53±11 yrs, BMI 26.8±5.5 kg/m2) and VAD removal at cardiac transplantation, and 24 controls (48±7 yrs, BMI 29.4±4.2 kg/m2). Clinical data were collected from institutional medical records. NGAL and cystatin C levels were measured by ELISA and eGFR calculated using MDRD formula. Results Patients with stable HF showed elevated NGAL and cystatin C levels compared to controls (114.2±52.3 ng/mL vs. 72.0±36.1 ng/mL, p<0.0001; cystatin C: 1490.4±576.1 ng/mL vs. 986.3±347.5 ng/mL, p=0.0026). Unlike cystatin C, NGAL increased in advanced HF requiring VAD implantation (158.7±74.8 ng/mL, p<0.001). On VAD, NGAL levels decreased (127.1±80.4 ng/mL, p=0.034). NGAL was higher in patients who developed right ventricular failure (187.8±66.0 vs. 130.9±67.0 ng/mL, p=0.03) and irreversible renal dysfunction (190.0±73.8 ng/mL vs. 133.8±54.2 ng/mL, p<0.05) while cystatin C, creatinine and eGFR were not different. NGAL correlated with eGFR (r=-0.2188, p=0.01). Conclusions NGAL levels correlate with HF severity and hemodynamic improvement after VAD placement. Our findings suggest a role of this novel biomarker as a marker of severity and prognosis in patients with HF.
    The Journal of Heart and Lung Transplantation 12/2014; · 5.61 Impact Factor
  • Source
    Konstantinos Drosatos, P Christian Schulze
    Circulation 11/2014; 130(20):1775-7. · 14.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Epicardial adipose tissue is a source of pro-inflammatory cytokines and has been linked to the development of coronary artery disease. No study has systematically assessed the relationship between local epicardial fat volume (EFV) and myocardial perfusion defects. We analyzed EFV in patients undergoing SPECT myocardial perfusion imaging combined with computed tomography (CT) for attenuation correction. Low-dose CT without contrast was performed in 396 consecutive patients undergoing SPECT imaging for evaluation of coronary artery disease. Regional thickness, cross-sectional areas, and total EFV were assessed. 295 patients had normal myocardial perfusion scans and 101 had abnormal perfusion scans. Mean EFVs in normal, ischemic, and infarcted hearts were 99.8 ± 82.3 cm(3), 156.4 ± 121.9 cm(3), and 96.3 ± 102.1 cm(3), respectively (P < 0.001). Reversible perfusion defects were associated with increased local EFV compared to normal perfusion in the distribution of the right (69.2 ± 51.5 vs 46.6 ± 32.0 cm(3); P = 0.03) and left anterior descending coronary artery (87.1 ± 76.4 vs 46.7 ± 40.6 cm(3); P = 0.005). Our results demonstrate increased regional epicardial fat in patients with active myocardial ischemia compared to patients with myocardial scar or normal perfusion on nuclear perfusion scans. Our results suggest a potential role for cardiac CT to improve risk stratification in patients with suspected coronary artery disease.
    Journal of Nuclear Cardiology 10/2014; · 2.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiac retransplantation is increasing in frequency. Recent data have shown that retransplantation outcomes are now comparable with primary transplantation. The use of mechanical circulatory support (MCS) as a bridge to retransplantation has similar post-retransplant outcomes to those without MCS, but the success of bridging patients to retransplant with MCS has not been well studied. From January 2000 to February 2014 at Columbia University Medical Center, 84 patients were listed for retransplantation. Of this cohort, 48 patients underwent retransplantation, 15 were bridged with MCS, 24 died, and 6 clinically improved. A retrospective analysis was performed examining waiting list time, survival to retransplantation, and survival after retransplant. The effect of the United Network of Organ Sharing (UNOS) allocation policy change in 2006 on waiting list time and MCS use was also investigated. Of 48 patients who underwent retransplantation, 11 were bridged with MCS. Overall 1-year survival to retransplantation was 81.3%. There was no significant difference in waiting list survival (p = 0.71) in those with and without MCS. Death from cardiac arrest or multiorgan failure with infection was more frequent in the medically managed group (p = 0.002). After the UNOS 2006 allocation policy change, waiting list time (599 ± 936 days in Era 1 vs 526 ± 498 days in Era 2, p = 0.65) and waiting list survival (p = 0.22) between eras were comparable, but there was a trend toward greater use of MCS (p = 0.13). Survival after retransplant was acceptable. The use of MCS as a bridge to cardiac retransplantation is a reasonable strategy. Copyright © 2014 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
    The Journal of Heart and Lung Transplantation 09/2014; · 5.61 Impact Factor
  • Journal of Cardiac Failure 08/2014; 20(8S):S104. · 3.07 Impact Factor
  • Journal of cardiac failure. 08/2014; 20(8S):S26.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Heart failure (HF) is associated with high morbidity and mortality and its incidence is increasing worldwide. MicroRNAs (miRNAs) are potential markers and targets for diagnostic and therapeutic applications, respectively. We determined myocardial and circulating miRNA abundance and its changes in patients with stable and end-stage HF before and at different time points after mechanical unloading by a left ventricular assist device (LVAD) by small RNA sequencing. miRNA changes in failing heart tissues partially resembled that of fetal myocardium. Consistent with prototypical miRNA– target-mRNA interactions, target mRNA levels were negatively correlated with changes in abundance for highly expressed miRNAs in HF and fetal hearts. The circulating small RNA profile was dominated by miRNAs, and fragments of tRNAs and small cytoplasmic RNAs. Heart- and muscle-specific circulating miRNAs (myomirs) increased up to 140-fold in advanced HF, which coincided with a similar increase in cardiac troponin I (cTnI) protein, the established marker for heart injury. These extracellular changes nearly completely reversed 3 mo following initiation of LVAD support. In stable HF, circulating miRNAs showed less than fivefold differences compared with normal, and myomir and cTnI levels were only captured near the detection limit. These findings provide the underpinning for miRNA-based therapies and emphasize the usefulness of circulating miRNAs as biomarkers for heart injury performing similar to established diagnostic protein biomarkers.
    Proceedings of the National Academy of Sciences 07/2014; 111(30):11151-11156. · 9.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Peripheral vascular disease (PVD) portends increased morbidity and mortality in patients with heart failure. In those with advanced heart failure, heart transplantation (HT) is the only causative therapy to increase survival. However, little is known about the impact of symptomatic PVD on survival of HT recipients in large multicenter cohorts. The aim of this study was to investigate an association between recipient symptomatic PVD and survival after HT. We analyzed 20,297 patients from the United Network of Organ Sharing data set. Survival analysis using a control cohort established by propensity matching was performed. There was an increased prevalence of traditional cardiovascular risk factors in 711 patients with symptomatic PVD compared with 19,586 patients without PVD. Patients with pretransplant symptomatic PVD had increased post-transplant mortality compared with those without PVD (1-, 5- and 10-year survival rate 91.5% vs 94.9%, 74.8% vs 82.6%, 48.6% vs 54.7%, respectively, log-rank p <0.001). On multivariate analysis based on the propensity matching, factors associated with a lower survival rate were presence of PVD (hazard ratio 1.20, 95% confidential interval 1.02 to 1.42, p = 0.030), and female gender (hazard ratio 1.22, 95% confidence interval 1.02 to 1.47, p = 0.034). In conclusion, patients with symptomatic PVD have a lower survival rate after HT. Symptomatic PVD should be considered an independent risk factor for poor prognosis in patients undergoing HT evaluation.
    The American Journal of Cardiology 07/2014; · 3.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and objectivePulmonary hypertension (PH) is a known complication in patients with interstitial lung disease (ILD). Cardiopulmonary exercise testing (CPET) is an essential tool for the assessment of patients with cardiac and pulmonary diseases due to its prognostic and therapeutic implications. Few studies have evaluated the relationship between CPET response and mean pulmonary artery pressures (mPAP) in ILD. The purpose of the present study was to determine and compare the potential correlations between CPET, 6-min walk test (6MWT), pulmonary function testing (PFT) and PH in patients with ILD being evaluated for lung transplantation.Methods The present study reviewed patients with ILD who received lung transplantations and had CPETs within 2 years before transplantation, right heart catheterizations, PFTs and 6MWTs within 4 months of CPET.ResultsA total of 72 patients with ILD were analysed; 36% had PH. There were significant correlations between mPAP and CPET parameters in patients with PH; but mPAP had no impact on percent of predicted diffusion capacity of the lung for carbon monoxide or 6-min walk distance (6MWD). CPET parameters were able to detect differences between levels of severity of PH through the use of the ratio of minute ventilation to rate of carbon dioxide production () and the partial pressure of end-tidal carbon dioxide.Conclusions This is the first study that analyses 6MWD, PFT and CPET in patients with ILD awaiting lung transplantation with and without PH. The present study demonstrates the significant impact of PH on exercise capacity and performance in patients with ILD awaiting lung transplantation.
    Respirology 06/2014; · 3.50 Impact Factor
  • The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 05/2014; · 5.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Declining physical function is common among systolic heart failure (HF) patients and heralds poor clinical outcomes. We hypothesized that coordinated shifts in expression of ubiquitin mediated atrophy-promoting genes are associated with muscle atrophy and contribute to decreased physical function. Systolic HF patients (left ventricular ejection fraction [LVEF] ≤40%) underwent skeletal muscle biopsies (non-dominant vastus lateralis) and comprehensive physical assessments. Skeletal muscle gene expression was assessed using real-time polymerase chain reaction. Aerobic function was assessed using cardiopulmonary exercise and 6 minute walk tests. Strength capacity was assessed using pneumatic leg press (maximum strength and power). Serological inflammatory markers were also assessed. 54 male patients (66.6±10.0 years) were studied; 24 systolic HF patients (mean LVEF=28.9±7.8%) and 30 age-matched controls. Aerobic and strength parameters were diminished in HF vs. controls. FoxO1 and FoxO3 were increased in HF vs. controls (7.9+6.2 vs. 5.0±3.5, 6.5 ±4.3 vs. 4.3±2.8, respectively, p≤0.05 in both). However, atrogin-1 and MuRF-1 were similar in both groups. PGC-1α was also increased in HF (7.9±5.4 vs. 5.3±3.6, p<0.05). Muscle levels of IGF-1 as well as serum levels of TNF-α, CRP, IL-1β, and IL-6 were similar in HF and controls. Expression of the atrophy-promoting genes FoxO1 and FoxO3 were increased in skeletal muscle in systolic HF compared to controls, but other atrophy gene expression patterns (atrogin-1 and MuRF-1) as well as growth promoting patterns (IGF-1) were similar. PGC-1α, a gene critical in enhancing mitochondrial function and moderating FoxO activity, may play an important counter-regulatory role to offset ubiquitin pathway-mediated functional decrements.
    Journal of cardiac failure 04/2014; · 3.07 Impact Factor
  • The Journal of Heart and Lung Transplantation 04/2014; 33(4):S169. · 5.61 Impact Factor
  • The Journal of Heart and Lung Transplantation 04/2014; 33(4):S118. · 5.61 Impact Factor
  • H. Yerebakan, R. Sorabella, M. Najjar, E. Castillero, V. Choi, U.P. Jorde, M.A. Farr, D.M. Mancini, Y. Naka, M.S. Maurer, P. Schulze, H. Takayama, I. George
    The Journal of Heart and Lung Transplantation 04/2014; 33(4):S55. · 5.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study examined the impact of the United Network for Organ Sharing (UNOS) policy changes for regional differences in waitlist time and mortality before and after heart transplantation. The 2006 UNOS thoracic organ allocation policy change was implemented to allow for greater regional sharing of organs for heart transplantation. We analyzed 36,789 patients who were listed for heart transplantation from January 1999 through April 2012. These patients were separated into 2 eras centered on the July 12, 2006 UNOS policy change. Pre- and post-transplantation characteristics were compared by UNOS regions. Waitlist mortality decreased nationally (up to 180 days: 13.3% vs. 7.9% after the UNOS policy change, p < 0.001) and within each region. Similarly, 2-year post-transplant mortality decreased nationally (2-year mortality: 17.3% vs. 14.6%; p < 0.001) as well as regionally. Waitlist time for UNOS status 1A and 1B candidates increased nationally 17.8 days on average (p < 0.001) with variability between the regions. The greatest increases were in Region 9 (59.2-day increase, p < 0.001) and Region 4 (41.2-day increase, p < 0.001). Although the use of mechanical circulatory support increased nearly 2.3-fold nationally in Era 2, significant differences were present on a regional basis. In Regions 6, 7, and 10, nearly 40% of those transplanted required left ventricular assist device bridging, whereas only 19.6%, 22.3%, and 15.5% required a left ventricular assist device in regions 3, 4, and 5, respectively. The 2006 UNOS policy change has resulted in significant regional heterogeneity with respect to waitlist time and reliance on mechanical circulatory support as a bridge to transplantation, although overall both waitlist mortality and post-transplant survival are improved.
    JACC. Heart failure. 04/2014; 2(2):166-77.
  • Donna M Mancini, P Christian Schulze
    Journal of the American College of Cardiology 01/2014; · 15.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The mammalian heart, the bodys largest energy consumer, has evolved robust mechanisms to tightly couple fuel supply with energy demand across a wide range of physiologic and pathophysiologic states. Yet, when compared to other organs, relatively little is known about the molecular machinery that directly governs metabolic plasticity in the heart. While previous studies have defined Kruppel like Factor 15 (KLF15) as a transcriptional repressor of path-ologic cardiac hypertrophy, a direct role for the KLF family in cardiac metabolism has not been previously established. We show in human heart samples that KLF15 is induced after birth and reduced in heart failure, a myocardial expression pattern that parallels reliance on lipid oxidation. Isolated working heart studies and unbiased transcriptomic profiling in Klf15 deficient hearts demonstrate that KLF15 is an essential regulator of lipid flux and metabolic homeostasis in the adult myocardium. An important mechanism by which KLF15 regulates its direct transcriptional targets is via interaction with p300 and recruitment of this critical co activator to promoters. This study establishes KLF15 as a key regulator of myocardial lipid utilization and is the first to implicate the KLF transcription factor family in cardiac metabo-lism.
    Journal of Biological Chemistry 01/2014; · 4.60 Impact Factor

Publication Stats

3k Citations
878.07 Total Impact Points


  • 2010–2014
    • Gracie Square Hospital, New York, NY
      New York City, New York, United States
  • 2008–2014
    • New York Presbyterian Hospital
      • Department of Cardiology
      New York City, New York, United States
    • Duke University Medical Center
      Durham, North Carolina, United States
  • 2013
    • CUNY Graduate Center
      New York City, New York, United States
    • Yale University
      New Haven, Connecticut, United States
  • 2002–2013
    • Brigham and Women's Hospital
      • • Department of Medicine
      • • Center for Brain Mind Medicine
      Boston, Massachusetts, United States
    • Heinrich-Heine-Universität Düsseldorf
      • Institute of Laser Medicine
      Düsseldorf, North Rhine-Westphalia, Germany
  • 2011
    • Columbia University
      • Division of Cardiology
      New York City, NY, United States
  • 1998–2007
    • University of Leipzig
      • Department of Cardiac Surgery
      Leipzig, Saxony, Germany
  • 2006
    • Boston Medical Center
      Boston, Massachusetts, United States
  • 2004–2006
    • Harvard Medical School
      • Department of Medicine
      Boston, Massachusetts, United States
    • The Forsyth Institute
      • Department of Cytokine Biology
      Cambridge, Massachusetts, United States
    • Massachusetts Institute of Technology
      • Department of Biological Engineering
      Cambridge, MA, United States
  • 2003
    • Harvard University
      Cambridge, Massachusetts, United States